Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression: A Randomized Controlled Trial | Cerebrovascular Disease | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Caplan GA. A Conceptual Model for Primary Prevention: Principles of Preventive Psychiatry. New York NY: Basic Books; 1964
2.
Committee on Prevention of Mental Disorders; Division of Biobehavioral Sciences and Mental Disorders.  Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Mrazek PJ, Haggerty RJ, eds. Washington, DC: National Academy Press; 1994
3.
Thom T, Haase N, Rosamond W,  et al.  Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.  Circulation. 2006;113(6):e85-e15116407573PubMedGoogle ScholarCrossref
4.
Aström M, Adolfsson R, Asplund K. Major depression in stroke patients: a 3-year longitudinal study.  Stroke. 1993;24(7):976-9828322398PubMedGoogle ScholarCrossref
5.
Berg A, Psych L, Palomaki H,  et al.  Poststroke depression—an 18-month follow-up.  Stroke. 2003;34(1):138-14312511765PubMedGoogle ScholarCrossref
6.
Burvill PW, Johnson GA, Jamrozik KD, Anderson CS, Stewart-Wynne EG, Chakera TMH. Prevalence of depression after stroke: the Perth Community Stroke Study.  Br J Psychiatry. 1995;166(3):320-3277788123PubMedGoogle ScholarCrossref
7.
House A, Dennis M, Mogridge L, Warlow C, Hawton K, Jones L. Mood disorders in the year after first stroke.  Br J Psychiatry. 1991;158:83-922015456PubMedGoogle ScholarCrossref
8.
Morris PLP, Robinson RG, Raphael B. Prevalence and course of depressive disorders in hospitalized stroke patients.  Int J Psychiatry Med. 1990;20(4):349-3642086522PubMedGoogle ScholarCrossref
9.
Robinson RG. The Clinical Neuropsychiatry of Stroke. 2nd ed. Cambridge, England: Cambridge University Press; 2006
10.
Palomäki H, Kaste M, Berg A, Lonqvisst R. Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mainserin with 6 month followup after therapy.  J Neurol Neurosurg Psychiatry. 1999;66(4):490-49410201422PubMedGoogle ScholarCrossref
11.
Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: results from a randomized placebo-controlled trial.  J Clin Psychiatry. 2006;67(7):1104-110916889454PubMedGoogle ScholarCrossref
12.
Rasmussen A, Lunde M, Poulsen DL, Sorensen K, Qvitzau S, Bech P. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients.  Psychosomatics. 2003;44(3):216-22112724503PubMedGoogle ScholarCrossref
13.
Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;23:56-6214399272PubMedGoogle ScholarCrossref
14.
Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis.  Int Clin Psychopharmacol. 2007;22(3):159-16617414742PubMedGoogle ScholarCrossref
15.
Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitryptyline and placebo for major depression in primary care.  BMJ. 1995;310(6977):441-4457873952PubMedGoogle ScholarCrossref
16.
Lincoln NB, Flannaghan T. Cognitive behavioral psychotherapy for depression following stroke: a randomized controlled trial.  Stroke. 2003;34(1):111-11512511760PubMedGoogle ScholarCrossref
17.
De Renzi E, Vignolo LA. The Token Test: a sensitive test to detect disturbances in aphasics.  Brain. 1962;85:665-67814026018PubMedGoogle ScholarCrossref
18.
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994
19.
Kunitz SC, Gross CR, Heyman A,  et al.  The pilot stroke data bank: definition, design and data.  Stroke. 1984;15(4):740-7466464070PubMedGoogle ScholarCrossref
20.
Tamminga CA, Nemeroff CB, Blakely RD,  et al.  Developing novel treatments for mood disorders: accelerating discovery.  Biol Psychiatry. 2002;52(6):589-60912361670PubMedGoogle ScholarCrossref
21.
Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.  Int Clin Psychopharmacol. 2005;20(3):131-13715812262PubMedGoogle ScholarCrossref
22.
Hegel MT, Barrett JE, Cornell JE, Oxman TE. Predictors of response to problem-solving treatment of depression in primary care.  Behav Ther. 2002;33(4):511-527Google ScholarCrossref
23.
Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV (SCID). New York, NY: Biometric Research, New York State Psychiatric Institute; 1995
24.
Fedoroff JP, Starkstein SE, Parikh RM, Price TR, Robinson RG. Are depressive symptoms non-specific in patients with acute stroke?  Am J Psychiatry. 1991;148(9):1172-11761882994PubMedGoogle Scholar
25.
Paradiso S, Ohkubo T, Robinson RG. Vegetative and psychological symptoms associated with depressed mood over the first two years after stroke.  Int J Psychiatry Med. 1997;27(2):137-1579565720PubMedGoogle ScholarCrossref
26.
Hamilton M. The assessment of anxiety state of rating.  Br J Med Psychol. 1959;32(1):50-5513638508PubMedGoogle ScholarCrossref
27.
Robinson RG, Kubos KL, Starr LB, Rao K, Price  TR. Mood disorders in stroke patients: importance of location of lesion.  Brain. 1984;107(pt 1):81-936697163PubMedGoogle ScholarCrossref
28.
Shimoda K, Robinson RG. Effects of anxiety disorder in impairment and recovery from stroke.  J Neuropsychiatry Clin Neurosci. 1998;10(1):34-409547464PubMedGoogle Scholar
29.
Kimura M, Robinson RG. Treatment of poststroke generalized anxiety disorder comorbid with poststroke depression: Merged analysis of nortriptyline trials.  Am J Geriatr Psychiatry. 2003;11(3):320-32712724111PubMedGoogle Scholar
30.
Hollingshead AB, Redlich FC. Social Class and Mental Illness: A Community Study. New York, NY: Wiley; 1958
31.
Forer S, Granger CV. Functional Independence Measure. Buffalo, NY: The Buffalo General Hospital, State University of New York at Buffalo; 1987
32.
Starr LB, Robinson RG, Price TR. The Social Functioning Exam: an assessment for stroke patients.  Soc Work Res Abstr. 1982;18(4):28-3310260031PubMedGoogle ScholarCrossref
33.
Starr LB, Robinson RG, Price TR. Reliability, validity, and clinical utility of the social functioning exam in the assessment of stroke patients.  Exp Aging Res. 1983;9(2):101-1066628488PubMedGoogle ScholarCrossref
34.
Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status. New York, NY: The Psychological Corp; 1998
35.
Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice.  Biol Psychiatry. 2006;59(11):990-99616368078PubMedGoogle ScholarCrossref
36.
Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods.  Stat Med. 1998;17(8):873-8909595617PubMedGoogle ScholarCrossref
37.
Bender R. Calculating confidence intervals for the number needed to treat.  Control Clin Trials. 2001;22(2):102-11011306148PubMedGoogle ScholarCrossref
38.
Shepherd J, Cobbe SM, Ford I,  et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group.  N Engl J Med. 1995;333(20):1301-13077566020PubMedGoogle ScholarCrossref
39.
Andersen G, Vestergaard K, Riis JO, Lauritzen L. Incidence of post-stroke depression during the first year in a large unselected stroke population determined using a valid standardized rating scale.  Acta Psychiatr Scand. 1994;90(3):190-1957810342PubMedGoogle ScholarCrossref
40.
Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier T. Nortriptyline versus fluoxetine in the treatment of depression and in short term recovery after stroke: a placebo controlled, double-blind study.  Am J Psychiatry. 2000;157(3):351-35910698809PubMedGoogle ScholarCrossref
41.
Rovner BW, Casten RJ, Hegel MT, Leiby BE, Tasman WS. Preventing depression in age-related macular degeneration.  Arch Gen Psychiatry. 2007;64(8):886-89217679633PubMedGoogle ScholarCrossref
42.
Morris PLP, Robinson RG, Andrezejewski P, Samuels J, Price TR. Association of depression with 10-year post-stroke mortality.  Am J Psychiatry. 1993;150(1):124-1298417554PubMedGoogle Scholar
43.
Morris PLP, Robinson RG, Samuels J. Depression, introversion and mortality following stroke.  Aust N Z J Psychiatry. 1993;27(3):443-4498250788PubMedGoogle ScholarCrossref
44.
House A, Knapp P, Bamford J, Vail A. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month.  Stroke. 2001;32(3):696-70111239189PubMedGoogle ScholarCrossref
45.
Williams LS, Ghose SS, Swindle RW. Depression and other mental health diagnoses increase mortality risk after ischemic stroke.  Am J Psychiatry. 2004;161(6):1090-109515169698PubMedGoogle ScholarCrossref
46.
Goldberg DP, Hiller VF. A scaled version of the General Health Questionnaire.  Psychol Med. 1979;9(1):139-145424481PubMedGoogle ScholarCrossref
47.
Jorge RE, Robinson RG, Arndt S, Starkstein SE. Mortality and post-stroke depression: a placebo controlled trial of antidepressants.  Am J Psychiatry. 2003;160(10):1823-182914514497PubMedGoogle ScholarCrossref
48.
Narushima K, Paradiso S, Moser DJ, Jorge R, Robinson RG. Effect of antidepressant therapy on executive function after stroke.  Br J Psychiatry. 2007;190:260-26517329748PubMedGoogle ScholarCrossref
49.
Narushima K, Robinson RG. The effect of early versus late antidepressant treatment on physical impairment associated with poststroke depression: is there a time-related therapeutic window?  J Nerv Ment Dis. 2003;191(10):645-65214555866PubMedGoogle ScholarCrossref
50.
Santarelli L, Saxe M, Gross C,  et al.  Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.  Science. 2003;301(5634):805-80912907793PubMedGoogle ScholarCrossref
51.
Wong ML, Licinio J. Research and treatment approaches to depression.  Nat Rev Neurosci. 2001;2(5):343-35111331918PubMedGoogle ScholarCrossref
52.
Feibel JH, Springer CJ. Depression and failure to resume social activities after stroke.  Arch Phys Med Rehabil. 1982;63(6):276-2787082155PubMedGoogle Scholar
53.
Schubert DSP, Taylor C, Lee S, Mentari A, Tamaklo W. Detection of depression in the stroke patient.  Psychosomatics. 1992;33(3):290-2941410202PubMedGoogle ScholarCrossref
Original Contribution
May 28, 2008

Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City (Drs Robinson, Jorge, and Moser); Department of Psychiatry, Carver College of Medicine and Department of Biostatistics, College of Public Health, University of Iowa (Ms Acion and Dr Arndt); Department of Neurology, University of Chicago, Chicago, Illinois (Drs Solodkin and Small); Weill Medical College of Cornell University at Burke Rehabilitation Hospital, White Plains, New York (Dr Fonzetti); and Departments of Psychiatry & Community & Family Medicine, Dartmouth Medical School, Hanover, New Hampshire (Dr Hegel).

JAMA. 2008;299(20):2391-2400. doi:10.1001/jama.299.20.2391
Abstract

Context Depression occurs in more than half of patients who have experienced a stroke. Poststroke depression has been shown in numerous studies to be associated with both impaired recovery in activities of daily living and increased mortality. Prevention of depression thus represents a potentially important goal.

Objective To determine whether treatment with escitalopram or problem-solving therapy over the first year following acute stroke will decrease the number of depression cases that develop compared with placebo medication.

Design, Setting, and Participants A multisite randomized controlled trial for prevention of depression among 176 nondepressed patients was conducted within 3 months following acute stroke from July 9, 2003, to October 1, 2007. The 12-month trial included 3 groups: a double-blind placebo-controlled comparison of escitalopram (n = 59) with placebo (n = 58), and a nonblinded problem-solving therapy group (n = 59).

Main Outcome Measures The main outcome measure was the development of major or minor poststroke depression based on symptoms elicited by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) and the diagnostic criteria from DSM-IV for depression due to stroke with major depressive-like episode or minor depression (ie, research criteria).

Results Patients who received placebo were significantly more likely to develop depression than individuals who received escitalopram (11 major and 2 minor cases of depression [22.4%] vs 3 major and 2 minor cases of depression [8.5%], adjusted hazard ratio [HR], 4.5; 95% confidence interval [CI], 2.4-8.2; P < .001) and also more likely than individuals who received problem-solving therapy (5 major and 2 minor cases of depression [11.9%], adjusted HR, 2.2; 95% CI, 1.4-3.5; P < .001). These results were adjusted for history of mood disorders and remained significant after considering possible confounders such as age, sex, treatment site, and severity of impairment in the model. Using an intention-to-treat conservative method of analyzing the data, which assumed that all 27 patients who did not start randomized treatment would have developed depression, and controlling for prior history of mood disorders, escitalopram was superior to placebo (23.1% vs 34.5%; adjusted HR, 2.2; 95% CI, 1.2-3.9; P = .007), while problem-solving therapy was not significantly better than placebo (30.5% vs 34.5%; adjusted HR, 1.1; 95% CI, 0.8-1.5; P = .51). Adverse events, including all-cause hospitalizations, nausea, and adverse effects associated with escitalopram were not significantly different between the 3 groups.

Conclusions In this study of nondepressed patients with recent stroke, the use of escitalopram or problem-solving therapy resulted in a significantly lower incidence of depression over 12 months of treatment compared with placebo, but problem-solving therapy did not achieve significant results over placebo using the intention-to-treat conservative method of analysis.

Trial Registration clinicaltrials.gov Identifier: NCT00071643

×